Heated chemo plus targeted drug shows promise in ovarian cancer trial
NCT ID NCT07460180
First seen Mar 20, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests whether adding a targeted drug (olaparib) to heated chemotherapy given during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III ovarian cancer will take olaparib pills before and after surgery. The goal is to find the best dose and check for side effects. This is an early-phase trial, so it focuses on safety and finding the right dose, not yet on a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NKI-AvL
RECRUITINGAmsterdam, 1066CX, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.